269 related articles for article (PubMed ID: 36347265)
1. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
Kalra PR; Cleland JGF; Petrie MC; Thomson EA; Kalra PA; Squire IB; Ahmed FZ; Al-Mohammad A; Cowburn PJ; Foley PWX; Graham FJ; Japp AG; Lane RE; Lang NN; Ludman AJ; Macdougall IC; Pellicori P; Ray R; Robertson M; Seed A; Ford I;
Lancet; 2022 Dec; 400(10369):2199-2209. PubMed ID: 36347265
[TBL] [Abstract][Full Text] [Related]
2. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of a randomised trial of intravenous iron in patients with heart failure.
Kalra PR; Cleland JG; Petrie MC; Ahmed FZ; Foley PW; Kalra PA; Lang NN; Lane RE; Macdougall IC; Pellicori P; Pope MTB; Robertson M; Squire IB; Thomson EA; Ford I
Heart; 2022 Nov; 108(24):1979-1985. PubMed ID: 35948408
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Ferric Derisomaltose on Cardiovascular and Noncardiovascular Events in Patients With Anemia, Iron Deficiency, and Heart Failure With Reduced Ejection Fraction.
Ray R; Ford I; Cleland JGF; Graham F; Ahmed FZ; Al-Mohammad A; Cowburn PJ; Critoph C; Kalra PA; Lane RE; Ludman A; Pellicori P; Petrie MC; Robertson M; Seed A; Squire I; Kalra PR; ; ; ;
J Card Fail; 2024 May; 30(5):682-690. PubMed ID: 37926238
[TBL] [Abstract][Full Text] [Related]
5. In HF with iron deficiency, IV ferric derisomaltose was associated with lower rates of HF hospitalization or CV death.
Lerman JB; Newby LK
Ann Intern Med; 2023 Apr; 176(4):JC40. PubMed ID: 37011388
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial.
Vanobberghen F; Lweno O; Kuemmerle A; Mwebi KD; Asilia P; Issa A; Simon B; Mswata S; Schmidlin S; Glass TR; Abdulla S; Daubenberger C; Tanner M; Meyer-Monard S
Lancet Glob Health; 2021 Feb; 9(2):e189-e198. PubMed ID: 33245866
[TBL] [Abstract][Full Text] [Related]
7. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
Cleland JGF; Kalra PA; Pellicori P; Graham FJ; Foley PWX; Squire IB; Cowburn PJ; Seed A; Clark AL; Szwejkowski B; Banerjee P; Cooke J; Francis M; Clifford P; Wong A; Petrie C; McMurray JJV; Thomson EA; Wetherall K; Robertson M; Ford I; Kalra PR;
Eur Heart J; 2024 Apr; 45(16):1410-1426. PubMed ID: 38446126
[TBL] [Abstract][Full Text] [Related]
9. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.
Khalafallah AA; Yan C; Al-Badri R; Robinson E; Kirkby BE; Ingram E; Gray Z; Khelgi V; Robertson IK; Kirkby BP
Lancet Haematol; 2016 Sep; 3(9):e415-25. PubMed ID: 27570088
[TBL] [Abstract][Full Text] [Related]
10. Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction.
Docherty KF; McMurray JJV; Kalra PR; Cleland JGF; Lang NN; Petrie MC; Robertson M; Ford I
ESC Heart Fail; 2024 Mar; ():. PubMed ID: 38549192
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.
Mebazaa A; Davison B; Chioncel O; Cohen-Solal A; Diaz R; Filippatos G; Metra M; Ponikowski P; Sliwa K; Voors AA; Edwards C; Novosadova M; Takagi K; Damasceno A; Saidu H; Gayat E; Pang PS; Celutkiene J; Cotter G
Lancet; 2022 Dec; 400(10367):1938-1952. PubMed ID: 36356631
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis.
Anker SD; Khan MS; Butler J; von Haehling S; Jankowska EA; Ponikowski P; Friede T
Eur J Heart Fail; 2023 Jul; 25(7):1080-1090. PubMed ID: 37062867
[TBL] [Abstract][Full Text] [Related]
14. Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function.
Macdougall IC; Ponikowski P; Stack AG; Wheeler DC; Anker SD; Butler J; Filippatos G; Göhring UM; Kirwan BA; Kumpeson V; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA
Clin J Am Soc Nephrol; 2023 Sep; 18(9):1124-1134. PubMed ID: 37382961
[TBL] [Abstract][Full Text] [Related]
15. Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
Mentz RJ; Garg J; Rockhold FW; Butler J; De Pasquale CG; Ezekowitz JA; Lewis GD; O'Meara E; Ponikowski P; Troughton RW; Wong YW; She L; Harrington J; Adamczyk R; Blackman N; Hernandez AF;
N Engl J Med; 2023 Sep; 389(11):975-986. PubMed ID: 37632463
[TBL] [Abstract][Full Text] [Related]
16. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
Mentz RJ; Ambrosy AP; Ezekowitz JA; Lewis GD; Butler J; Wong YW; De Pasquale CG; Troughton RW; O'Meara E; Rockhold FW; Garg J; Samsky MD; Leloudis D; Dugan M; Mundy LM; Hernandez AF;
Circ Heart Fail; 2021 May; 14(5):e008100. PubMed ID: 34003690
[TBL] [Abstract][Full Text] [Related]
17. Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure.
Caravita S; Faini A; Vignati C; Pelucchi S; Salvioni E; Cattadori G; Baratto C; Torlasco C; Contini M; Villani A; Malfatto G; Perger E; Lombardi C; Piperno A; Agostoni P; Parati G
Eur J Heart Fail; 2022 Oct; 24(10):1940-1949. PubMed ID: 35867685
[TBL] [Abstract][Full Text] [Related]
18.
Bisch SP; Woo L; Ljungqvist O; Nelson G
BMJ Open; 2023 Nov; 13(11):e074649. PubMed ID: 37945297
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
Ponikowski P; Mentz RJ; Hernandez AF; Butler J; Khan MS; van Veldhuisen DJ; Roubert B; Blackman N; Friede T; Jankowska EA; Anker SD
Eur Heart J; 2023 Dec; 44(48):5077-5091. PubMed ID: 37632415
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis.
Vukadinović D; Abdin A; Emrich I; Schulze PC; von Haehling S; Böhm M
Clin Res Cardiol; 2023 Jul; 112(7):954-966. PubMed ID: 37074386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
